Compare AVLN & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | QNST |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2026 | 2009 |
| Metric | AVLN | QNST |
|---|---|---|
| Price | $26.27 | $16.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $61.80 | $22.80 |
| AVG Volume (30 Days) | 266.3K | ★ 734.6K |
| Earning Date | 11-25-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1650.00 |
| EPS | N/A | ★ 1.40 |
| Revenue | N/A | ★ $282,140,000.00 |
| Revenue This Year | N/A | $15.97 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | ★ N/A | $12.06 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.24 | $10.29 |
| 52 Week High | $40.17 | $22.29 |
| Indicator | AVLN | QNST |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 52.07 |
| Support Level | $24.90 | $14.09 |
| Resistance Level | $30.45 | $18.02 |
| Average True Range (ATR) | 1.73 | 0.54 |
| MACD | 0.45 | 0.24 |
| Stochastic Oscillator | 72.23 | 69.92 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. The company operates as one reportable segment. The company generates majority of revenue from United States. The company's products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and Cloud Control Media.